These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34545429)

  • 21. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE.
    Gaujoux-Viala C; Hudry C; Zinovieva E; Herman-Demars H; Flipo RM
    Rheumatology (Oxford); 2021 Dec; 61(1):270-280. PubMed ID: 33774669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
    Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
    Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
    Katada H; Yukawa N; Urushihara H; Tanaka S; Mimori T; Kawakami K
    Clin Rheumatol; 2015 May; 34(5):949-56. PubMed ID: 24420724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
    Curtis JR; Zhang J; Xie F; Beukelman T; Chen L; Fernandes J; Ginsberg S; Spettell C; Yun H; Saag KG; Schiff M
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1604-11. PubMed ID: 24942466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients.
    Desai RJ; Solomon DH; Jin Y; Liu J; Kim SC
    J Manag Care Spec Pharm; 2017 Aug; 23(8):809-814. PubMed ID: 28737992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab.
    Schmalzing M; Behrens F; Schwaneck EC; Koehm M; Greger G; Gnann H; Burkhardt H; Tony HP
    Medicine (Baltimore); 2020 May; 99(19):e20201. PubMed ID: 32384515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.
    Fitzpatrick R; Scott DG; Keary I
    Clin Rheumatol; 2013 Nov; 32(11):1605-12. PubMed ID: 23835658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
    Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Bourret J; Koenig A
    J Manag Care Spec Pharm; 2016 Mar; 22(3):209-18. PubMed ID: 27003550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis.
    Kisiel B; Kruszewski R; Juszkiewicz A; Raczkiewicz A; Bachta A; Tłustochowicz M; Staniszewska-Varga J; Kłos K; Duda K; Bogusławska-Walecka R; Płoski R; Tłustochowicz W
    J Immunol Res; 2015; 2015():759610. PubMed ID: 26090499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?
    Favalli EG; Biggioggero M; Meroni PL
    Autoimmun Rev; 2014 Nov; 13(11):1102-8. PubMed ID: 25172238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.
    Tornero-Molina J; Andreu JL; Martín-Martínez MA; Corominas H; Pérez Venegas JJ; Román-Ivorra JA; Sánchez-Alonso F
    Reumatol Clin (Engl Ed); 2019; 15(6):338-342. PubMed ID: 29273497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.